Articles tagged with Psoriasis
Research finds psoriasis patients are 26% more likely to die from cardiovascular disease and 18% more likely to die from all causes after a heart attack. The study emphasizes the need for a more aggressive approach to secondary prevention of cardiovascular disease in psoriasis patients.
A meta-analysis of biologic therapies for chronic plaque psoriasis found no significant increase in cardiovascular events among patients treated with these medications. However, the analysis highlights limitations of current clinical trial designs, which may not detect rare or long-term adverse events.
Researchers found that patients with RA or psoriasis who were treated with TNF inhibitors or hydroxychloroquine had a lower risk of developing diabetes. The study suggests an association between these medications and reduced diabetes risk, but the cause is not yet known.
A study of nearly 14,000 patients with rheumatoid arthritis or psoriasis found that certain disease-modifying antirheumatic drugs reduced the risk of developing type 2 diabetes. The findings suggest a possible role for immunosuppression in preventing diabetes among patients with systemic inflammatory disorders.
A Kaiser Permanente study of 711,000 children found that obese kids are almost 40% more likely to have psoriasis than normal-weight peers. Teens with psoriasis also had higher cholesterol levels, regardless of weight status.
A cohort study analyzing over 3,600 patients with severe psoriasis found a 53% increased incidence of major adverse cardiac events compared to the general population. Patients with severe psoriasis have an additional 6% ten-year risk of MACE.
Researchers at Ruhr-University Bochum have found that fumaric acid salts exhibit neuroprotective effects in Multiple Sclerosis by detoxifying radicals and supporting nerve cell survival. This discovery offers new hope for treating MS, potentially combining with existing medications.
A study published in Archives of Dermatology reveals that nearly 40% of individuals with psoriasis also have features of the metabolic syndrome. The most common feature among individuals with psoriasis is abdominal obesity, followed by high triglyceride levels and low levels of HDL cholesterol.
Scientists at the University of Michigan have identified four new DNA hotspots that may aid in developing new treatments for psoriasis. The study, published in Nature Genetics, builds on past work by U-M researchers and provides a better understanding of the hereditary factors of the disease.
A genome-wide association study of 2,622 patients with psoriasis and 5,667 healthy individuals has identified six regions of the genome associated with the condition. The study found evidence for an interaction between two associated regions – HLA-C and ERAP1, providing new insights into psoriasis susceptibility.
The University of Michigan Health System has received the first 1,250 DNA samples from the National Psoriasis Victor Henschel BioBank, the largest single collection of psoriasis DNA samples. The samples will be used to identify new genes that increase a person's risk factor for developing psoriasis and examine its connection with other...
Regular beer consumption is linked to an increased risk of developing psoriasis. Non-light beer drinkers have a higher risk compared to those who don't drink beer or consume light beer.
A recent study published in Archives of Dermatology found that individuals with psoriasis are at a higher risk of developing depression, anxiety, and suicidality. The study estimated that there are over 10,400 cases of depression, 7,100 cases of anxiety, and 350 cases of suicidality related to psoriasis each year.
A recent study found that narrowband UV-B treatment can increase serum levels of vitamin D in patients with psoriasis while clearing the condition. The study also showed significant improvements in psoriasis severity scores and dermatology-related quality of life.
A study published in Archives of Dermatology found that individuals with psoriasis who were obese at age 18 had an increased risk of developing psoriatic arthritis. The study also identified other predictors, including younger age at psoriasis onset and larger body surface areas affected by the condition.
The cost of psoriasis treatments has increased faster than inflation, with newer biologic therapies being significantly more expensive. Costs for systemic therapy range from $1,197 to $27,577, with phototherapy and biologics having varying price ranges.
A new international study has found that ustekinumab is more effective than etanercept in treating moderate to severe psoriasis. Ustekinumab showed a 75% improvement in symptoms in 67.5% and 73.8% of patients, compared to 56.8% for etanercept.
Researchers at Helmholtz Munich have discovered Th22 cells, a previously unknown subset of T helper cells that aid in tissue repair and prevent inflammation. The newly found cells hold promise for developing new treatment methods for inflammatory skin diseases and potentially also allergic respiratory diseases.
Research found that psoriasis patients have weaker brain response to disgusted faces, indicating a potential coping strategy to protect against social stigma. The study suggests that this adaptation may also apply to other stigmatizing skin conditions like acne or scarring.
Researchers identify three genetic variations on chromosome 6 associated with psoriasis, with HLA-Cw*0602 being the strongest link. The study found that individuals with all three variants are nearly nine times more likely to develop the disease.
A study found that psoriasis is associated with an increased risk of cardiovascular disease, including ischemic heart disease, cerebrovascular disease, and peripheral artery disease. Patients with psoriasis were also more likely to die from these conditions, highlighting the need for vigilance in screening for cardiovascular risk factors.
A study of 78,061 women found that those with psoriasis were 63% more likely to develop diabetes and 17% more likely to develop hypertension than women without psoriasis. Systemic inflammation in psoriasis may be a biologically plausible explanation for the association.
A new phase III trial found that golimumab significantly improved active psoriatic arthritis and associated skin and nail psoriasis. The study also showed improved physical function, health-related quality of life, and enthesitis symptoms.
Researchers at the University of Tokyo identified a novel biomarker to monitor acute kidney injury, while a study found that the unfolded protein response contributes to nerve cell death in Alzheimer's Disease. Additionally, a bacterial toxin disrupts intestinal epithelial barrier function, leading to systemic infection.
A new web-based therapy programme, eTIPS, is being tested to help people with psoriasis manage their condition better. The programme uses cognitive behaviour therapy to address the psychological discomfort caused by the visible nature of the condition.
Low-dose acitretin therapy shows promise in reducing nail psoriasis symptoms, with 25-33% of patients experiencing complete or near-complete clearing. The treatment also demonstrates safety and effectiveness in improving quality of life for patients suffering from severe nail psoriasis.
A randomized, double-blind study found ustekinumab to be effective in treating moderate-to-severe psoriatic arthritis, with significant improvements in pain and stiffness. The treatment showed sustained benefits up to 36 weeks after initial dosing.
Researchers discovered seven new genetic variants that increase the risk of psoriasis, clustering in pathways involving IL-23 and NF-kappaB. The absence of skin genes LCE3B and LCE3C also increases the risk of the disease, suggesting an inappropriate immune response.
A recent study identified four new DNA 'hotspots' linked to psoriasis, an autoimmune disease that causes scaling and inflammation. The study also confirmed the association of two previously identified sites with psoriasis, revealing potential genetic markers for the disease.
Researchers have discovered DNA hotspots associated with psoriasis, an autoimmune disease characterized by skin patches and joint pain. The study identified four novel genes linked to the condition, providing potential targets for new treatments.
Psoriasis affects 0.6-4.8% of the world's population, impairing financial status and well-being. Online support groups provide valuable resources, anonymity, and improved quality of life for patients. The study found that 49.5% of participants perceived improvements in psoriasis severity since joining an online community.
Researchers discovered a significant association between psoriasis and high levels of leptin, an obesity-related hormone that contributes to metabolic abnormalities. The study also found that body weight loss can decrease leptin levels and improve insulin sensitivity, potentially reducing the risk of cardiovascular diseases.
A randomized trial found that indigo naturalis ointment significantly improved scaling, erythema, and induration in patients with treatment-resistant psoriasis. After 12 weeks, the treated plaques showed an 81% improvement compared to a 26% improvement for non-medicated ointment-treated lesions.
The guidelines aim to ensure physicians worldwide are aware of available treatments for patients with psoriatic arthritis. Newer medications inhibiting tumor necrosis factor (TNF) are recommended for consideration.
Two studies have shown that ustekinumab is effective in treating moderate-to-severe psoriasis, with dosing every 12 weeks maintaining efficacy in most patients. The PHOENIX studies found that 67-76% of patients achieved PASI 75 at week 12, with long-term response maintained in those given maintenance treatment.
A new calcineurin inhibitor ISA247 has been shown to be safe and effective in treating moderate to severe psoriasis. The study found a strong correlation between drug dose and response, allowing for more accurate dosing to minimize side effects.
A comprehensive study of the genetic basis of psoriasis has discovered seven new sites of common DNA variation that increase the risk of this skin condition. The variations were found to be strongly linked to psoriatic arthritis and other autoimmune disorders, paving the way for more targeted therapies.
Scientists discovered seven new DNA variations linked to psoriasis, which also increased the risk of four autoimmune diseases. The study found a strong genetic component underlying these conditions, paving the way for targeted treatments.
A recent study by the University of Pennsylvania School of Medicine found that curcumin, an active ingredient in turmeric, had a low response rate in patients with psoriasis. Despite laboratory evidence showing its potential, the study suggests that the placebo effect or natural remission may be responsible for the limited results.
Ustekinumab therapy maintains clinically meaningful improvement in moderate to severe plaque psoriasis through 1 year, with 87% and 91% of patients sustaining a 75% PASI improvement. The study also found sustained response rates at 66% and 73% for PASI 90.
Patients with moderate to severe plaque psoriasis receiving REMICADE experienced significant skin clearance improvements across four body regions, including head, trunk, and extremities. At week 10, 71-79% of patients achieved a PASI 75 improvement, with even greater success at 39-52% achieving a PASI 90 response.
Researchers found that Enbrel significantly reduced levels of C-reactive protein in patients with moderate to severe plaque psoriasis, indicating a systemic inflammatory disease. The study also showed that heavier patients had higher CRP levels and that Enbrel decreased these levels in overweight and obese patients.
A study found that neutralizing IL-22 prevents psoriasis-like disease in mice by reducing skin thickening and inflammatory responses. Administering IL-22 into normal mice induced psoriasis-like skin lesions, supporting the role of IL-22 in the disease.
A new injectable drug, etanercept, has been shown to dramatically reduce psoriasis flare-ups in pediatric patients. The study found that 57% of patients achieved a 75% or greater improvement in symptoms, compared to 11% on placebo.
Patients with severe psoriasis have a 50% higher risk of death compared to those without the condition. The study found that men and women with severe psoriasis died an average of 3.5 and 4.4 years earlier, respectively.
In a Phase 3 biologic study, golimumab significantly improved joint and skin manifestations of psoriatic arthritis in patients with active disease. The treatment achieved primary and major secondary endpoints, demonstrating sustained improvements through six months.
Researchers will focus on three projects utilizing different strategies to study psoriasis, including a novel photodynamic therapy and analysis of the role of S100A8/9 protein. The goal is to control inflammation and develop safer therapies for patients with the debilitating disease.
A Phase 3 trial found that ustekinumab achieved significant improvements in psoriasis symptoms and quality of life measures, with over two-thirds of patients experiencing at least a 75% reduction in psoriasis symptoms. The treatment resulted in substantial proportions of patients maintaining responses through week 28.
Researchers found that green tea slowed skin cell growth and regulated genes involved in skin cell life cycles, potentially treating psoriasis and dandruff. However, more human studies are needed to determine the full effects of this treatment.
Researchers at Karolinska Institutet discovered that microRNA molecules, specifically miR-203, are significantly upregulated in psoriasis and may be involved in regulating keratinocytes. This study suggests that microRNA therapies could become more effective than traditional medicines targeting individual proteins.
A phase 3 randomized trial found that extended exposure to etanercept improved measures of disease severity in patients with moderate to severe psoriasis. The treatment was well-tolerated, with no increased risk of adverse events or infections.
A survey of 1,142 patients with chronic moderate to severe plaque psoriasis found that nearly 40% are not receiving treatment. The study also showed that those with severe psoriasis are more likely to have a lower household income.
Patients treated with REMICADE experienced significant improvements in work and daily activities, with mean increases of 2.9-3.1 points compared to little improvement in placebo-treated patients. Psoriasis is an inflammatory disorder that can cause physical pain and emotional distress, impacting productivity.
Patients with severe psoriasis receiving Remicade experienced significant improvements in skin and nail symptoms. The treatment achieved PASI 75 in over three-quarters of patients at week 10.
A study by Mayo Clinic researchers has found that people with psoriasis are more likely to develop heart disease, including heart attacks and heart failure. The study, which followed 622 adults with psoriasis and a control group of 622 people, found significant increases in cardiovascular events among those with psoriasis.
A study published in JAMA Network found that adults with psoriasis, particularly those with severe forms of the condition, are at a higher risk for heart attacks. The research also revealed that younger patients with severe psoriasis have a significantly increased relative risk compared to other major cardiac risk factors.
A study published in JAMA found that psoriasis patients are at a higher risk of heart attack, particularly those with severe psoriasis. Younger patients with severe psoriasis had the highest relative risk of heart attack, similar to other major cardiac risk factors.
New data reinforce the safety profile of ENBREL, confirming its efficacy for up to 2.5 years with no significant increase in adverse events. The study also shows that patients who experience interruption in treatment can regain similar positive efficacy results after re-initiating therapy.
Researchers found that short-term application of topical corticosteroids followed by maintenance treatment with a less potent agent can effectively manage intertriginous psoriasis. The study also showed that 0.1 percent betamethasone was more effective than 1 percent pimecrolimus in reducing symptoms.
Researchers at Karolinska Institutet found that mast cells can contribute to diseases like psoriasis and cancer through a previously unknown activation mechanism. The study suggests that the CD30 protein stimulates mast cell release of proteins regulating inflammatory cell recruitment.